Optimizing the antitumor efficacy of cisplatin low doses by the co-treatment with ethylenediamine tetra acetic acid in EAC-bearing mice

Cancer disease remains one of the most cause of death worldwide. Thedrawbacks that were associated to the chemotherapy treatments are impetusfor finding more efficacious, and better tolerated new drugs. This study wasconducted to optimize the low doses of cisplatin (Cis) antitumor effect by theco-treatment of ethylenediamine tetra acetic acid (EDTA) in EAC-bearingmice. Sixty-four female CD-1 mice were divided into eight groups (n = 8) asfollows: Gp1 was a negative control. Gp2 had inoculated with 1×106 EACcells/mouse interperitoneally (i.p.). Gp3, Gp4 and Gp5 had inoculated withthe same number of EAC-cells as in Gp2, then injected with 0.125, 0.250 or0.5 mg/Kg of Cis i.p, respectively. Gp6, Gp7 and Gp8 had inoculated withEAC-cells as in Gp2, then injected with the low doses of Cis as in Gp3- G5in combination with EDTA (50 mg/Kg), respectively. At day 14, all groupswere bled to collect sera for biochemical assessments. The tumor ascites wascollected for determining the total tumor volume and total tumor counts.Liver tissues were harvested for histopathological investigations. The resultsshowed that co-treatment of EDTA (50 mg/Kg) along with the low doses ofCis (0.125, 0.25 or 50 mg/Kg) led to significant reduction in tumor volume,tumor cells count, improved the liver, kidney functions, and antioxidantstatus. Among all the treated EAC-bearing mice groups, mice that had acombined treatment with Cis (0.5 mg/Kg) and EDTA (50 mg/Kg) showedthe highest antitumor effect with highly improvements in the liver functionsand architectures.